Patents by Inventor Axel Neubauer
Axel Neubauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115687Abstract: The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against Streptococcus infections in pigs. The invention provides a ?FolT mutant of a bacterium having reduced capacity to transport folate, wherein said capacity has been reduced by functionally deleting folate transporter (FolT) function. The invention also provides a method to reduce virulence of a bacterium comprising reducing the capacity of said bacterium to transport folate.Type: ApplicationFiled: May 12, 2023Publication date: April 11, 2024Inventors: Alaina INGEBRITSON, Axel NEUBAUER, Hilda Elizabeth SMITH, Astrid DE GREEFF
-
Patent number: 11684663Abstract: The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against Streptococcus infections in pigs. The invention provides a ?FolT mutant of a bacterium having reduced capacity to transport folate, wherein said capacity has been reduced by functionally deleting folate transporter (FolT) function. The invention also provides a method to reduce virulence of a bacterium comprising reducing the capacity of said bacterium to transport folate.Type: GrantFiled: November 10, 2017Date of Patent: June 27, 2023Inventors: Alaina Ingebritson, Axel Neubauer, Hilda Elizabeth Smith, Astrid De Greeff
-
Publication number: 20220226456Abstract: The invention relates to bacterial infections, vaccines directed against those infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against Streptococcus infections in pigs. The invention provides a ?FolT mutant of a bacterium having reduced capacity to transport folate, wherein said capacity has been reduced by functionally deleting folate transporter (FolT) function. The invention also provides a method to reduce virulence of a bacterium comprising reducing the capacity of said bacterium to transport folate.Type: ApplicationFiled: November 10, 2017Publication date: July 21, 2022Inventors: Alaina INGEBRITSON, Axel NEUBAUER, Hilda Elizabeth SMITH, Astrid DE GREEFF
-
Patent number: 10758602Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.Type: GrantFiled: December 19, 2017Date of Patent: September 1, 2020Inventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
-
Patent number: 10512680Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.Type: GrantFiled: January 19, 2016Date of Patent: December 24, 2019Inventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
-
Publication number: 20180271969Abstract: The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype conjugated to a carrier protein. The immunogenic composition is useful for the protection of disease in an animal subject.Type: ApplicationFiled: October 6, 2016Publication date: September 27, 2018Applicants: Boehringer Ingelheim Vetmedica, Inc., Université de Montréal, Université du Québec à MontréalInventors: Marcelo GOTTSCHALK, Guillaume GOYETTE-DESJARDINS, Jennifer Anne Kempker, Axel NEUBAUER, René ROY, Mariela SEGURA, Tze Chieh SHIAO
-
Publication number: 20180125957Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 19, 2017Publication date: May 10, 2018Inventors: Dianna M. Murphy JORDAN, Brian Thomas MARTINSON, Christine Margaret MUEHLENTHALER, Axel NEUBAUER, Arun V. IYER
-
Patent number: 9878027Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.Type: GrantFiled: December 20, 2013Date of Patent: January 30, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
-
Publication number: 20160136254Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.Type: ApplicationFiled: January 19, 2016Publication date: May 19, 2016Inventors: DIANNA M. MURPHY JORDAN, BRIAN THOMAS MARTINSON, CHRISTINE MARGARET MUEHLENTHALER, AXEL NEUBAUER, ARUN V. IYER
-
Patent number: 9273281Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.Type: GrantFiled: December 20, 2013Date of Patent: March 1, 2016Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Dianna M. Murphy Jordan, Brian Thomas Martinson, Christine Margaret Muehlenthaler, Axel Neubauer, Arun V. Iyer
-
Publication number: 20140186394Abstract: The present invention relates to a method for the preparation of an immunogenic composition for the treatment and/or prophylaxis of mycoplasma infections in a subject comprising the cultivation of mycoplasma bacteria in a serum-reduced or swine serum-free, eukaryotic cell system; obtaining an antigen of the mycoplasma bacteria; and addition of a pharmaceutically acceptable carrier. Further, the present invention relates to the immunogenic composition obtainable by said method and a method for immunizing a subject comprising the administration of said immunogenic composition to a subject.Type: ApplicationFiled: December 20, 2013Publication date: July 3, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Dianna M. Murphy JORDAN, Brian Thomas MARTINSON, Christine Margaret MUEHLENTHALER, Axel NEUBAUER, Arun V. IYER
-
Publication number: 20140186393Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 20, 2013Publication date: July 3, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Dianna M. Murphy JORDAN, Brian Thomas MARTINSON, Christine Margaret MUEHLENTHALER, Axel NEUBAUER, Arun V. IYER
-
Publication number: 20110150770Abstract: An immunogenic composition or vaccine, and method of treatment are provided by the present invention. The immunogenic composition is useful for treating, preventing, and lessening the severity of clinical symptoms associated with disease-causing organisms in swine, utilizing one or more Porcine Teschovirus antigen(s) along with an antigen of the other disease-causing organism in swine and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 9, 2010Publication date: June 23, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Elida BAUTISTA, Dianna M. Murphy JORDAN, Axel NEUBAUER, Abby Rae PATTERSON, Michael B. Roof, Eric M. VAUGHN, Joseph G. Victoria
-
Publication number: 20080241190Abstract: The present invention is broadly concerned with vaccination of horses against proliferative enteritis, preferably equine proliferative ileitis, which is caused by an obligate intracellular bacterium Lawsonia Intracellularis (L. intracellularis). Specifically, the invention provides for a method of providing immune protection against L. intracellularis by vaccinating horses, preferably foals starting from one (1) week of age. Preferably the foals are vaccinated with about 4.9 log 10 to about 6.9 log 10 of a live modified L. intracellularis bacteria per dose.Type: ApplicationFiled: November 9, 2007Publication date: October 2, 2008Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.Inventors: Jeremy Kroll, Axel Neubauer, Philip Utley, Michael Roof, Juergen Daemmgen, Knut Elbers